Search

A recent study conducted by researchers from Ohio State University focused on evaluating prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. The study, known as ECLIPSE, included 478 patients and found that the 6-month and 1-year cumulative incidence of nonrelapse mortality after auto-HCT were 0.9% and 1.1%, respectively. The research highlighted the safety and long-term efficacy of auto-HCT, even in patients with high-risk disease traditionally considered chemotherapy refractory, providing valuable insights for ongoing transplant vs no transplant trials. [Extracted from the article]

A recent report from Mayo Clinic in Rochester, Minnesota, discusses the biological characteristics of Classical Hodgkin Lymphoma (cHL), highlighting the presence of Hodgkin Reed Sternberg (HRS) cells and the tumor microenvironment's role in promoting HRS cell growth. The research emphasizes the aberrancy and constitutive activation of core signal transduction pathways in cHL, as well as genetic lesions contributing to dysregulated pathways. While advancements in therapy have been made through understanding cHL biology, further research into additional mechanisms may lead to new treatment opportunities in the future. [Extracted from the article]

A recent study from Mayo Clinic provides an update on the diagnosis, risk-stratification, and management of Hodgkin lymphoma (HL). HL is an uncommon B-cell lymphoid malignancy that affects approximately 8570 new patients annually in the United States. The study highlights the importance of accurately assessing the stage of the disease for selecting appropriate therapy. Risk-adapted therapy is based on the histology, stage, and prognostic features of the disease. Newer agents, such as brentuximab vedotin and anti-PD-1 antibodies, are now incorporated into frontline therapy. High-dose chemotherapy followed by an autologous stem cell transplant is the standard of care for most patients who relapse following initial therapy. For patients who fail this treatment, other options such as brentuximab vedotin, PD-1 blockade, non-myeloablative allogeneic transplant, or participation in a clinical trial should be considered. [Extracted from the article]

A recent study conducted by researchers at the University of Cincinnati explores the relationship between cancer and paraneoplastic glomerular disease (PGD), a condition that arises from tumor cell products and leads to renal dysfunction. PGD is rare but significant, as it can indicate the onset of cancer and often does not respond to standard treatments for kidney disease. The study emphasizes the importance of early diagnosis and tailored treatment for both kidney disease and associated cancers. The research provides an overview of PGDs, their clinicopathological features, related cancers, and mechanisms. [Extracted from the article]

A recent study conducted in Durham, North Carolina, explored the neurocognitive dysfunction experienced by survivors of childhood Hodgkin lymphoma (HL). The study found that HL survivors demonstrated higher concentrations of markers of inflammation and oxidative stress compared to controls. These biomarkers were associated with worse neurocognitive outcomes, such as visuomotor processing speed, attention, memory, and executive function. The researchers concluded that inflammation and oxidative stress may be potential targets for future intervention trials to improve neurocognitive function in HL survivors. [Extracted from the article]

A recent study conducted at the Princess Margaret Cancer Centre in Toronto, Canada focused on very late relapse in Hodgkin lymphoma (HL), a rare event that occurs more than 5 years after initial diagnosis. The study found that male gender and increased age were risk factors for inferior survival in patients with very late relapse. The use of autologous stem cell transplantation (ASCT) at first relapse did not have a significant impact on time to second progression or overall survival. The researchers concluded that further study is needed to determine optimal therapy for preventing and treating very late relapse in HL. [Extracted from the article]

A recent study conducted by investigators at Georgetown University focuses on the evolving treatment paradigms for Hodgkin lymphoma (HL). HL is a highly curable B-cell malignancy that relies on the immune microenvironment and immune escape mechanisms. The addition of brentuximab vedotin and checkpoint inhibitors has led to significant changes in the treatment landscape. The researchers suggest further studies to determine the effectiveness and long-term toxicity of these novel agents in improving cure rates and managing HL at all stages of the disease. [Extracted from the article]

A recent study conducted in community oncology settings in the United States examined the use of positron emission tomography-computed tomography (PET-CT) scans and Deauville 5-point scale (5PS) score reporting for stage III/IV classic Hodgkin lymphoma (cHL) patients. The study found that there was under-reporting of Deauville 5PS scores for interim PET-CT scans, with standardized uptake value (SUV) results being provided instead. The researchers concluded that there is a need for educational opportunities to improve consistency in reporting and utilization of Deauville 5PS scores for treatment de-escalation or escalation. This study provides valuable insights for clinicians and researchers in the field of oncology. [Extracted from the article]

Researchers at Tufts Medical Center in Boston, Massachusetts conducted a survey to evaluate the role of caregivers in treatment decision-making for patients with classic Hodgkin lymphoma (cHL) in the USA. The survey included 209 caregivers, and the results showed that spouse/partner caregivers were more involved in caregiving at symptom onset and treatment option discussions with physicians. Cure was identified as the top treatment goal for caregivers, and while caregivers reported good health-related quality of life (HRQoL), nearly 30% of employed caregivers reported work impairment. The study highlights the importance of understanding the caregiver experience and providing support for their needs. [Extracted from the article]

Keywords: Vancouver; Canada; North and Central America; Cancer; Health and Medicine; Hematology; Immunoproliferative Disorders; Lymphatic Diseases and Conditions; Lymphoma; Lymphoproliferative Disorders; Oncology; Pediatrics EN Vancouver Canada North and Central America Cancer Health and Medicine Hematology Immunoproliferative Disorders Lymphatic Diseases and Conditions Lymphoma Lymphoproliferative Disorders Oncology Pediatrics 979 979 1 07/17/23 20230717 NES 230717 2023 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on Oncology - Lymphoma. Vancouver, Canada, North and Central America, Cancer, Health and Medicine, Hematology, Immunoproliferative Disorders, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Oncology, Pediatrics Keywords for this news article include: Vancouver, Canada, North and Central America, Cancer, Health and Medicine, Hematology, Immunoproliferative Disorders, Lymphatic Diseases and Conditions, Lymphoma, Lymphoproliferative Disorders, Oncology, Pediatrics, BC Cancer Agency. [Extracted from the article]

For more information on this research see: Radiation-induced sarcomas following childhood cancer - A Canadian Sarcoma Research and Clinical Collaboration Study (CanSaRCC). Keywords: Toronto; Canada; North and Central America; Cancer; Diagnostics and Screening; Health and Medicine; Oncology; Pediatrics; Sarcomas EN Toronto Canada North and Central America Cancer Diagnostics and Screening Health and Medicine Oncology Pediatrics Sarcomas 433 433 1 05/29/23 20230602 NES 230602 2023 JUN 3 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Cancer is the subject of a report. [Extracted from the article]